TY - JOUR
T1 - Delivering precision oncology to patients with cancer
AU - Mateo, Joaquin
AU - Steuten, Lotte
AU - Aftimos, Philippe
AU - André, Fabrice
AU - Davies, Mark
AU - Garralda, Elena
AU - Geissler, Jan
AU - Husereau, Don
AU - Martinez-Lopez, Iciar
AU - Normanno, Nicola
AU - Reis-Filho, Jorge S.
AU - Stefani, Stephen
AU - Thomas, David M.
AU - Westphalen, C. Benedikt
AU - Voest, Emile
N1 - Publisher Copyright:
© 2022, Springer Nature America, Inc.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.
AB - With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.
UR - http://www.scopus.com/inward/record.url?scp=85128792334&partnerID=8YFLogxK
U2 - 10.1038/s41591-022-01717-2
DO - 10.1038/s41591-022-01717-2
M3 - Article
C2 - 35440717
AN - SCOPUS:85128792334
SN - 1078-8956
VL - 28
SP - 658
EP - 665
JO - Nature Medicine
JF - Nature Medicine
IS - 4
ER -